Stoeckli Sandro J, Pfaltz Madeleine, Ross Gary L, Steinert Hans C, MacDonald D G, Wittekind Christian, Soutar David S
Department of Otorhinolaryngology, Head and Neck Surgery, University Hospital, Frauenklinikstrasse 24, Zurich, CH-8091, Switzerland.
Ann Surg Oncol. 2005 Nov;12(11):919-24. doi: 10.1245/ASO.2005.11.024. Epub 2005 Sep 19.
The Second International Conference on Sentinel Node Biopsy in Mucosal Head and Neck Cancer was hosted by the Department of Otorhinolaryngology, Head and Neck Surgery of the University Hospital in Zurich, Switzerland, from September 12 to 13, 2003. The aims of this conference were to present the results of validation studies and to achieve a consensus on methodological requirements.
More than 80 delegates from 20 countries attended the conference. The presented validation studies were summarized and compared with the literature. Consensus was achieved concerning requirements for lymphatic mapping and histopathologic work-up.
Twenty centers presented results on 379 patients with cN0 disease. Sentinel nodes were identified in 366 (97%) of 379. Of these 366, 103 (29%) were positive for occult metastasis, and 263 (71%) were negative. Of those 263 patients, 11 patients (4%) showed nodal disease not revealed by the sentinel lymph node biopsy (SNB). The negative predictive value of a negative sentinel node for the remaining neck was 96%. The consensus conference resulted in the use of a radiotracer, lymphoscintigraphy, and a handheld gamma probe for lymphatic mapping as minimal requirements. The use of conventional hematoxylin and eosin staining and immunohistochemistry for cytokeratin is mandatory. Step-sectioning of the entire node at intervals of 150 mum is recommended.
The conference attracted delegates from all over the world, thus underscoring the high interest in the topic. With regard to the presented data and the data from the literature, SNB for early oral and oropharyngeal cancer is sufficiently validated. The consensus conference resulted in the definition of minimal methodological requirements for accurate SNB.
2003年9月12日至13日,瑞士苏黎世大学医院耳鼻咽喉头颈外科主办了第二届头颈黏膜癌前哨淋巴结活检国际会议。本次会议的目的是展示验证研究结果并就方法学要求达成共识。
来自20个国家的80多名代表参加了会议。对所展示的验证研究进行了总结并与文献进行了比较。就淋巴绘图和组织病理学检查的要求达成了共识。
20个中心展示了379例cN0期疾病患者的研究结果。379例患者中,366例(97%)发现了前哨淋巴结。在这366例中,103例(29%)隐匿转移呈阳性,263例(71%)呈阴性。在这263例患者中,11例(4%)出现了前哨淋巴结活检(SNB)未发现的淋巴结疾病。前哨淋巴结阴性对其余颈部的阴性预测值为96%。共识会议确定,作为最低要求,使用放射性示踪剂、淋巴闪烁显像和手持式γ探测器进行淋巴绘图。必须使用传统苏木精和伊红染色以及细胞角蛋白免疫组织化学。建议对整个淋巴结以150μm的间隔进行连续切片。
本次会议吸引了来自世界各地的代表,从而凸显了对该主题的高度关注。就所展示的数据和文献数据而言,早期口腔和口咽癌的SNB已得到充分验证。共识会议确定了准确进行SNB的最低方法学要求。